Related Experiment Video
Updated: Feb 28, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
Interleukin-1 blockade for the treatment of pericarditis
Leo F Buckley1, Michele M Viscusi2, Benjamin W Van Tassell1
1Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA USA.
Abstract:
Pericarditis is a debilitating condition that results from profound inflammation of the pericardial tissue. Between 10 and 15% of first episodes of acute pericarditis will be followed by several episodes refractory to conventional treatment. Current standard of care for pericarditis treatment includes high-dose non-steroidal anti-inflammatory drugs, colchicine, and systemic corticosteroids, each associated with potentially severe toxicities and nominal efficacy. Interleukin-1 (IL-1), an apical pro-inflammatory cytokine, plays an important role as an autocrine magnifier of systemic inflammation in pericarditis. Interruption of the IL-1 circuit has been shown to have a favourable risk profile in several disease states. In this review, we discuss the growing body of evidence which supports the use of IL-1 blockade in the treatment of recurrent pericarditis as well as provide practical considerations for the use of IL-1 blockade in clinical practice.
Related Concept Videos
Pericarditis III: Medical Management
Myocarditis III: Medical Management
Pericarditis I: Introduction
Pericarditis IV: Nursing Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Pericarditis II: Clinical Features and Diagnostic Tests

